Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Prog Mol Biol Transl Sci. 2021;182:29-79. doi: 10.1016/bs.pmbts.2021.01.024. Epub 2021 Mar 19.
Novel gene therapy treatments for inherited retinal diseases have been at the forefront of translational medicine over the past couple of decades. Since the discovery of CRISPR mechanisms and their potential application for the treatment of inherited human conditions, it seemed inevitable that advances would soon be made using retinal models of disease. The development of CRISPR technology for gene therapy and its increasing potential to selectively target disease-causing nucleotide changes has been rapid. In this chapter, we discuss the currently available CRISPR toolkit and how it has been and can be applied in the future for the treatment of inherited retinal diseases. These blinding conditions have until now had limited opportunity for successful therapeutic intervention, but the discovery of CRISPR has created new hope of achieving such, as we discuss within this chapter.
在过去的几十年里,新型基因治疗方法在遗传性视网膜疾病的转化医学领域处于领先地位。自从发现 CRISPR 机制及其在治疗遗传性人类疾病方面的潜在应用以来,利用疾病的视网膜模型取得进展似乎是不可避免的。CRISPR 基因治疗技术的发展及其选择性靶向致病核苷酸变化的潜力正在迅速增加。在本章中,我们讨论了目前可用的 CRISPR 工具包,以及它已经并且将来如何应用于遗传性视网膜疾病的治疗。这些致盲疾病迄今为止成功治疗干预的机会有限,但 CRISPR 的发现为实现这一目标带来了新的希望,正如我们在本章中所讨论的那样。